Difficulty: Medium
Average Score: 88%
Practice
A 9mo-old infant develops a left adrenal mass; histological examination with genetic characteristics confirms neuroblastoma. Which of the following carries a better outcome?
Correct answer
B
Rationale
In pediatric oncology, understanding the genetic characteristics of neuroblastoma is crucial for determining prognosis and treatment. In this scenario, the correct answer is B) hyperdiploidy, which carries a better outcome. Hyperdiploidy refers to the presence of extra copies of chromosomes in the tumor cells, which is associated with a favorable prognosis in neuroblastoma. This genetic feature is linked to a lower risk of disease progression and better response to treatment.
Option A) amplification of the MYCN proto-oncogene is a well-known poor prognostic factor in neuroblastoma. MYCN amplification is associated with aggressive tumor behavior and resistance to therapy, leading to a worse outcome.
Option C) loss of heterozygosity of 17q chromosome and Option D) loss of 1p chromosome are also negative prognostic factors in neuroblastoma. These genetic alterations are associated with high-risk disease features and poorer treatment response, resulting in a less favorable outcome for the patient.
Educationally, this question highlights the importance of integrating genetic information into clinical decision-making for pediatric oncology patients. Understanding the impact of specific genetic alterations on disease prognosis can guide healthcare providers in tailoring treatment strategies and prognostic discussions with patients and their families. It emphasizes the need for a multidisciplinary approach involving oncologists, geneticists, and other specialists to optimize patient care and outcomes in pediatric oncology.
Option A) amplification of the MYCN proto-oncogene is a well-known poor prognostic factor in neuroblastoma. MYCN amplification is associated with aggressive tumor behavior and resistance to therapy, leading to a worse outcome.
Option C) loss of heterozygosity of 17q chromosome and Option D) loss of 1p chromosome are also negative prognostic factors in neuroblastoma. These genetic alterations are associated with high-risk disease features and poorer treatment response, resulting in a less favorable outcome for the patient.
Educationally, this question highlights the importance of integrating genetic information into clinical decision-making for pediatric oncology patients. Understanding the impact of specific genetic alterations on disease prognosis can guide healthcare providers in tailoring treatment strategies and prognostic discussions with patients and their families. It emphasizes the need for a multidisciplinary approach involving oncologists, geneticists, and other specialists to optimize patient care and outcomes in pediatric oncology.